TABLE 1.
Baseline characteristics of patients who did and did not develop neutropenia
| Characteristic | Value for: |
P value | |
|---|---|---|---|
| Nonneutropenic patients (n = 32) | Neutropenic patients (n = 7) | ||
| Age, median (25th–75th percentile) | 50.5 (40.75–60.75) | 44 (26–54) | 0.129a |
| BMI, median (25th–75th percentile) | 31.55 (25.40–38.83) | 23.9 (22.2–26.2) | 0.024a |
| Creatinine clearance, median (25th–75th percentile) | 90 (67.99–141.25) | 105 (93.00–109.00) | 0.360a |
| Male sex, n (%) | 24 (75) | 2 (28.6) | 0.030b |
| White race, n (%) | 28 (87.5) | 7 (100) | 0.614c |
| History of malignancy, n (%) | 2 (6.1) | 1 (14.3) | 0.457b |
| Baseline neutropenic med, n (%) | 13 (41.9) | 3 (42.9) | 1b |
| Charlson comorbidity index, median (25th–75th percentile) | 2 (0.25–3) | 1 (0–3) | 0.359a |
| Primary site of infection, n (%) | 0.249c | ||
| Skin/skin structure | 7 (22) | 1 (14) | |
| Orthopedic | 17 (53) | 3 (43) | |
| Endovascular | 1 (3) | 2 (29) | |
| Pulmonary | 6 (19) | 1 (14) | |
| Other | 1 (3) | 0 | |
| Baseline ANC (thousands), median (25th–75th percentile) | 8.4 (6.3–15.7) | 6.5 (5.4–10.3) | 0.300a |
| Duration of ceftaroline therapy (days), median (25th–75th percentile) | 25.5 (14.25–38.25) | 23 (19.5–51.5) | 0.755a |
a
Determined by Wilcoxon rank sum test.
b
Determined by Fisher's exact test.
c
Determined by Pearson chi-square test.